EU negative opinion for BioPartners' Biferonex for MS
This article was originally published in Scrip
Executive Summary
BioPartners GmbH's Biferonex (interferon beta-1a) has received a negative opinion from the EU's CHMP, which said the company had failed to prove its efficacy for the treatment of relapsing-remitting multiple sclerosis. The company said that it plans to appeal the decision.